NCT04128332Completed
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery in Pancreatic Adenocarcinoma: A Window of Opportunity Feasibility Study
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 8 Oct 2019
- Start date
- Oct 2020
- Primary completion date
- Jan 2025
- Lead sponsor
- CCTU- Cancer Theme
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT04128332
What you commit to
- Study type: Interventional
- Participants enrolled: 10
- From Oct 2020 to the primary completion date, Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous abdominal radiotherapy
Other illness
- Any condition or abnormalities that in the judgement of the investigator/surgeon/clinical oncologist would place the patient at undue risk
Other
- Women who are known to be pregnant
- Women of child-bearing potential who are unwilling to use 2 highly effective forms of contraception during the study treatment period
Who the study is looking for
- Have given written informed consent to participate in stage 1
- Be aged 16 years or over at the time of signing the informed consent form
- Presence of a hypodense pancreatic mass on contrast enhanced CT scan highly suspicious of operable primary pancreatic cancer as assessed by a pancreatic multi-disciplinary team (MDT)
- Have not had pre-operative systemic therapy or radiotherapy
- Have participated in stage 1 of the study
- Have confirmed histological or cytological diagnosis of primary pancreatic adenocarcinoma OR radiological evidence of pancreatic head mass with supportive cytological or histological findings.
- Be scheduled to undergo pancreatico-duodenectomy (Whipple's) resection.
- Written informed consent to participate in stage 2
- Aged 16 years or over at the time of signing informed consent
- Have not had pre-operative systemic therapy or radiotherapy
- ECOG Performance status 0-1
- Adequate renal function: GFR ≥ 60
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Addenbrookes Hospital Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.